22.677 articles found

[The feasibility of synthetic enhancer substances for preventive nanotherapy].

Miklya I.

Neuropsychopharmacol Hung · 2010-09-01

PMID: 20962359

[Medicamental treatment of schizophrenia].

Lotstra F, Lestienne S, De Nayer A.

Rev Med Brux · 2010-09-01

PMID: 21089395

[Development of gene therapy in major brain diseases].

Fan L, Jiang XG.

Yao Xue Xue Bao · 2010-09-01

PMID: 21351564

Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial.

Wolz M, Löhle M, Strecker K, Schwanebeck U, Schneider C, Reichmann H, Grählert X, Schwarz J, Storch A.

J Neural Transm (Vienna) · 2010-08-29

DOI: 10.1007/s00702-010-0472-xPMID: 20803300

[Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment].

Thobois S, Ardouin C, Schmitt E, Lhommée E, Klinger H, Xie J, Lagrange C, Kistner A, Aya Kombo M, Fleury V, Poisson A, Fraix V, Broussolle E, Pollak P, Krack P.

Rev Neurol (Paris) · 2010-08-23

DOI: 10.1016/j.neurol.2010.07.006PMID: 20739041

Comment on "A systematic review of the efficacy of globus pallidus stimulation in the treatment of Parkinson's disease".

Zrinzo L, Hariz MI.

J Clin Neurosci · 2010-08-23

DOI: 10.1016/j.jocn.2010.06.005PMID: 20739183

Hyperthyroidism "masked" the levodopa response in newly diagnosed Parkinson's disease patients.

Prakash KM, Kek PC.

Parkinsonism Relat Disord · 2010-08-21

DOI: 10.1016/j.parkreldis.2010.07.009PMID: 20729126

Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease.

Müller T, Muhlack S.

Parkinsonism Relat Disord · 2010-08-16

DOI: 10.1016/j.parkreldis.2010.07.012PMID: 20719554

The effects of levodopa and ongoing deep brain stimulation on subthalamic beta oscillations in Parkinson's disease.

Giannicola G, Marceglia S, Rossi L, Mrakic-Sposta S, Rampini P, Tamma F, Cogiamanian F, Barbieri S, Priori A.

Exp Neurol · 2010-08-14

DOI: 10.1016/j.expneurol.2010.08.011PMID: 20713047

USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES

BARBARAS RONALD, ONICIU DANIELA CARMEN, DASSEUX JEAN-LOUIS, SCOTT ROBERT A, WETTERAU JOHN R.

· 2010-08-13

Use of PPAR delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases

BARBARAS RONALD, ONICIU DANIELA CARMEN, DASSEUX JEAN-LOUIS, SCOTT ROBERT A, WETTERAU JOHN R.

· 2010-08-13

Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments.

Raskin S, Durst R.

Med Hypotheses · 2010-08-12

DOI: 10.1016/j.mehy.2010.07.024PMID: 20708340